Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 01, 2007. The report serves as a notification to the market regarding the Company's total voting rights and capital structure as of January 31, 2007, in conformity with Disclosure and Transparency Rules 5.6.1R.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure and voting rights.
- Issued Share Capital: 5,997,132,010 Ordinary shares of 25p each.
- Treasury Shares: 247,572,678 Ordinary shares.
- Total Voting Rights: 5,749,559,332.
Material Changes
The filing text does not provide a clear value or description of material changes versus the prior comparable period. The document is a static notification of share capital status as of the reporting date.
Guidance, Outlook, and Risks
The filing text does not provide clear values for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document contains no forward-looking statements or risk disclosures beyond the regulatory requirement to notify the market of voting rights.
Important Facts for Investors to Verify
- Verify the calculation of total voting rights (5,749,559,332) by subtracting treasury shares from issued share capital.
- Confirm the share price and market capitalization using the issued share count of 5,997,132,010.
- Check subsequent filings for financial performance data, as this 6-K contains no operational or financial results.